Warum ich Anteile an Ontrak kaufe?
eröffnet am 21.10.20 07:44:35 von
neuester Beitrag 08.08.24 14:33:28 von
neuester Beitrag 08.08.24 14:33:28 von
Beiträge: 117
ID: 1.332.684
ID: 1.332.684
Aufrufe heute: 0
Gesamt: 9.367
Gesamt: 9.367
Aktive User: 0
ISIN: US6833733024 · WKN: A3EJLV · Symbol: HY10
0,1968
EUR
+0,20 %
+0,0004 EUR
Letzter Kurs 16.09.24 Tradegate
Neuigkeiten
| Titel |
|---|
12.09.24 · Business Wire (engl.)  |
11.09.24 · Business Wire (engl.) |
05.09.24 · Business Wire (engl.) |
29.08.24 · Business Wire (engl.) |
15.08.24 · Business Wire (engl.) |
Werte aus der Branche Gesundheitswesen
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,5200 | +550,00 | |
| 7,3500 | +42,72 | |
| 2,2603 | +29,90 | |
| 8,4000 | +24,44 | |
| 1,1020 | +22,44 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 3,2000 | -16,75 | |
| 0,9700 | -18,49 | |
| 1,4600 | -21,51 | |
| 0,5700 | -29,72 | |
| 1,0100 | -59,60 |
Beitrag zu dieser Diskussion schreiben
Feedback
Geil - eben wurde eine neue Partnerschaft mit einem Health Plan verkündet. Ich bleibe dabei, das wird noch was 💪🏼
https://www.stocktitan.net/news/OTRK/ontrak-announces-new-co…
https://www.stocktitan.net/news/OTRK/ontrak-announces-new-co…
Heute kommen Zahlen nachbörslich 👋🏼
Antwort auf Beitrag Nr.: 76.164.733 von H2Power am 29.07.24 09:52:36Kurs zeigt auf jeden Fall wieder in die richtige Richtung
Antwort auf Beitrag Nr.: 76.164.535 von lisa46 am 29.07.24 09:26:52Hoffentlich bleibt es kein Strohfeuer, bisher kannte der Kurs nur eine Richtung.
Antwort auf Beitrag Nr.: 76.164.247 von H2Power am 29.07.24 08:44:21Es wurden enorm Kosten abgebaut. Aktuell gibt es wieder sechs Stellen-Ausschreibungen und die Nachrichten in letzter Zeit passen auch gut.
Das geht in die richtige Richtung. Und der Chart sieht auch lecker aus.
Das geht in die richtige Richtung. Und der Chart sieht auch lecker aus.
Trading Spotlight
Antwort auf Beitrag Nr.: 76.163.452 von lisa46 am 28.07.24 21:04:43Was macht Dich so zuversichtlich?
Bin wieder ordentlich rein in ONTRAK. Das wird die Rebound-Geschichte schlechthin…
Es kommen nun zwar vermehrt News rein, heute zur Kooperation mit Sentara Health, aber an der Aktie geht das mittlerweile komplett vorbei.
Und in Kurzfassung zur Kapitalerhöhung. Ganz frisch im November initiiert: 5,5 Mio. USD zu 0,6 USD / Aktie eingesammelt. Ordentliche Verwässerung, kein Wunder, dass der Kurs auf diesem Stand erstmal zementiert ist.
Zudem gibt es noch einen Haufen Optionen mit Ausübungspreis 0,85 USD. Da dürfte mit Blick nach oben kurstechnisch rein theoretisch dann erstmal ein gewisser Deckel liegen.
Zielumsatz 2023 von 12 bis 14 Mio. USD bestätigt.
Hier noch die Quelle zu den Kapitalmaßnahmen: https://ontrakhealth.com/investors/press-releases/?qmodStory…
"On November 14, 2023, the Company announced the closing of its previously announced public offering of:
4,592,068 shares of its common stock and 9,184,136 warrants to purchase up to 9,184,136 shares of its common stock at a combined public offering price of $0.60 per share of common stock and accompanying warrants, and
5,907,932 pre-funded warrants to purchase up to 5,907,932 shares of its common stock and 11,815,864 warrants to purchase up to 11,815,864 shares of its common stock at a combined public offering price of $0.5999 per pre-funded warrant and accompanying warrants, which represents the per share public offering price for the common stock and accompanying warrants less the $0.0001 per share exercise price for each pre-funded warrant.
The Company estimates net proceeds of approximately $5.5 million from the public offering described above.
In addition, concurrent with the public offering described above, the Company announced the closing of its previously announced concurrent private placement (the “Private Placement”) of $11.0 million worth of unregistered pre-funded warrants to purchase shares of the Company's common stock and unregistered warrants to purchase shares of the Company's common stock to Acuitas. The Company issued 18,333,333 pre-funded warrants to purchase up to 18,333,333 shares of its common stock and 36,666,666 warrants to purchase up to 36,666,666 shares of its common stock at a purchase price of $0.5999 per pre-funded warrant and accompanying warrants, which represents the per share public offering price for the common stock and accompanying warrants less the $0.0001 per share exercise price for each pre-funded warrant. The warrants accompanying the pre-funded warrants have an exercise price of $0.85 per share. The exercisability of such warrants are subject to stockholder approval and, if such approval is obtained, will expire on the fifth anniversary of the date of such approval. The consideration for the Private Placement Securities purchased by Acuitas consisted of (a) the $6.0 million of escrowed funds then held in the escrow account, and (b) a reduction of the aggregate amounts outstanding under the Keep Well Notes (after giving effect to the Notes Conversion) to $2.0 million (the “Surviving Note”). Prior to the closing of the public offering and private placement, Acuitas converted approximately $16.3 million of outstanding senior secured convertible notes, leaving $2.0 million of Surviving Note."
Zudem gibt es noch einen Haufen Optionen mit Ausübungspreis 0,85 USD. Da dürfte mit Blick nach oben kurstechnisch rein theoretisch dann erstmal ein gewisser Deckel liegen.
Zielumsatz 2023 von 12 bis 14 Mio. USD bestätigt.
Hier noch die Quelle zu den Kapitalmaßnahmen: https://ontrakhealth.com/investors/press-releases/?qmodStory…
"On November 14, 2023, the Company announced the closing of its previously announced public offering of:
4,592,068 shares of its common stock and 9,184,136 warrants to purchase up to 9,184,136 shares of its common stock at a combined public offering price of $0.60 per share of common stock and accompanying warrants, and
5,907,932 pre-funded warrants to purchase up to 5,907,932 shares of its common stock and 11,815,864 warrants to purchase up to 11,815,864 shares of its common stock at a combined public offering price of $0.5999 per pre-funded warrant and accompanying warrants, which represents the per share public offering price for the common stock and accompanying warrants less the $0.0001 per share exercise price for each pre-funded warrant.
The Company estimates net proceeds of approximately $5.5 million from the public offering described above.
In addition, concurrent with the public offering described above, the Company announced the closing of its previously announced concurrent private placement (the “Private Placement”) of $11.0 million worth of unregistered pre-funded warrants to purchase shares of the Company's common stock and unregistered warrants to purchase shares of the Company's common stock to Acuitas. The Company issued 18,333,333 pre-funded warrants to purchase up to 18,333,333 shares of its common stock and 36,666,666 warrants to purchase up to 36,666,666 shares of its common stock at a purchase price of $0.5999 per pre-funded warrant and accompanying warrants, which represents the per share public offering price for the common stock and accompanying warrants less the $0.0001 per share exercise price for each pre-funded warrant. The warrants accompanying the pre-funded warrants have an exercise price of $0.85 per share. The exercisability of such warrants are subject to stockholder approval and, if such approval is obtained, will expire on the fifth anniversary of the date of such approval. The consideration for the Private Placement Securities purchased by Acuitas consisted of (a) the $6.0 million of escrowed funds then held in the escrow account, and (b) a reduction of the aggregate amounts outstanding under the Keep Well Notes (after giving effect to the Notes Conversion) to $2.0 million (the “Surviving Note”). Prior to the closing of the public offering and private placement, Acuitas converted approximately $16.3 million of outstanding senior secured convertible notes, leaving $2.0 million of Surviving Note."
Und hier jetzt noch die wichtige Passage zur Refinanzierung / Patronatserklärung mit dem Private-Equity-Akteur Acuitas Investments, LLC:
"On October 31, 2023, the Company and Acuitas Capital entered into a Fifth Amendment to the Master Note Purchase Agreement, as amended (the "Fifth Amendment"), which, among other things, amended the definition of Qualified Financing to replace $10.0 million with $8.0 million, and in the event the Company completes a Qualified Financing, as defined in the Keep Well Agreement, the following are provided: i) the conversion of Keep Well Notes plus accrued and unpaid interest thereon, less $7.0 million, ii) in lieu of the provision set forth in the Fourth Amendment concerning investment of Escrowed Funds in an offering (which is described below), the Company and Acuitas to consummate a private placement which would consist of the escrowed funds and $5.0 million of Keep Well Notes in pre-funded warrants. In addition, the maturity date of the remaining $2.0 million Keep Well Note was changed from September 30, 2024 to the date that is two years and six months after the closing date of the offering (May 14, 2026), unless it becomes due and payable in full earlier, whether by acceleration or otherwise."
"On October 31, 2023, the Company and Acuitas Capital entered into a Fifth Amendment to the Master Note Purchase Agreement, as amended (the "Fifth Amendment"), which, among other things, amended the definition of Qualified Financing to replace $10.0 million with $8.0 million, and in the event the Company completes a Qualified Financing, as defined in the Keep Well Agreement, the following are provided: i) the conversion of Keep Well Notes plus accrued and unpaid interest thereon, less $7.0 million, ii) in lieu of the provision set forth in the Fourth Amendment concerning investment of Escrowed Funds in an offering (which is described below), the Company and Acuitas to consummate a private placement which would consist of the escrowed funds and $5.0 million of Keep Well Notes in pre-funded warrants. In addition, the maturity date of the remaining $2.0 million Keep Well Note was changed from September 30, 2024 to the date that is two years and six months after the closing date of the offering (May 14, 2026), unless it becomes due and payable in full earlier, whether by acceleration or otherwise."
Durchsuchen